Servier Presentations at ISPNO 2026 Highlight Neuro-Oncology Leadership and Expanding Glioma Portfolio

▤ Summary

Servier is presenting new and updated neuro-oncology data at ISPNO 2026, including two oral presentations on the Phase 2 FIREFLY-1 study of OJEMDA (tovorafenib). The company is also sharing a caregiver survey that examines communication challenges around pediatric low-grade glioma diagnosis and treatment. The release highlights Servier's expanding glioma portfolio and its broader oncology and neurology strategy following the Day One Biopharmaceuticals acquisition. The announcement reinforces OJEMDA's clinical evidence base and Servier's focus on rare cancers and pediatric neuro-oncology.

▦ Linked Companies